Capital Research Global Investors Boosts Position in Masimo Co. (NASDAQ:MASI)

Capital Research Global Investors lifted its stake in Masimo Co. (NASDAQ:MASI - Free Report) by 80.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,454,975 shares of the medical equipment provider's stock after buying an additional 1,094,647 shares during the quarter. Capital Research Global Investors owned about 4.59% of Masimo worth $405,807,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Jones Financial Companies Lllp bought a new stake in Masimo during the fourth quarter valued at about $27,000. UMB Bank n.a. lifted its stake in Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock worth $32,000 after purchasing an additional 123 shares in the last quarter. Trust Co. of Vermont bought a new position in shares of Masimo during the 4th quarter valued at about $33,000. Blue Trust Inc. grew its position in shares of Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 71 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 64 shares during the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MASI has been the subject of several research analyst reports. Wells Fargo & Company raised their price target on Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a report on Thursday, April 10th. Raymond James upped their price target on shares of Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research note on Friday, December 27th. Finally, Piper Sandler lifted their price objective on shares of Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $194.80.

Masimo Trading Down 0.3 %

Masimo stock traded down $0.48 during midday trading on Friday, reaching $162.16. The stock had a trading volume of 69,631 shares, compared to its average volume of 659,453. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $8.76 billion, a price-to-earnings ratio of 111.97 and a beta of 1.28. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $194.88. The company has a fifty day moving average of $166.04 and a 200 day moving average of $165.25.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. On average, analysts anticipate that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Craig B. Reynolds sold 2,053 shares of the firm's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares of the company's stock, valued at $2,754,601.53. This trade represents a 11.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now directly owns 24,172 shares of the company's stock, valued at approximately $4,048,568.28. This represents a 55.38 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 9.70% of the company's stock.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.